TY - JOUR AU - Barretina, J. PY - 2010 DA - 2010// TI - Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy JO - Nat Genet VL - 42 UR - https://doi.org/10.1038/ng.619 DO - 10.1038/ng.619 ID - Barretina2010 ER - TY - JOUR AU - Sinha, S. AU - Peach, A. H. PY - 2010 DA - 2010// TI - Diagnosis and management of soft tissue sarcoma JO - BMJ VL - 341 UR - https://doi.org/10.1136/bmj.c7170 DO - 10.1136/bmj.c7170 ID - Sinha2010 ER - TY - JOUR AU - Yang, J. PY - 2009 DA - 2009// TI - Genetic aberrations in soft tissue leiomyosarcoma JO - Cancer Lett VL - 275 UR - https://doi.org/10.1016/j.canlet.2008.06.013 DO - 10.1016/j.canlet.2008.06.013 ID - Yang2009 ER - TY - JOUR AU - Vivanco, I. AU - Sawyers, C. L. PY - 2002 DA - 2002// TI - The phosphatidylinositol 3-Kinase AKT pathway in human cancer JO - Nat Rev Cancer VL - 2 UR - https://doi.org/10.1038/nrc839 DO - 10.1038/nrc839 ID - Vivanco2002 ER - TY - JOUR AU - Hernando, E. PY - 2007 DA - 2007// TI - The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas JO - Nat Med VL - 13 UR - https://doi.org/10.1038/nm1560 DO - 10.1038/nm1560 ID - Hernando2007 ER - TY - JOUR AU - Bathan, A. J. AU - Constantinidou, A. AU - Pollack, S. M. AU - Jones, R. J. PY - 2013 DA - 2013// TI - Diagnosis, prognosis, and management of leiomyosarcoma: recognition of anatomic variants JO - Curr Opin VL - 025 ID - Bathan2013 ER - TY - STD TI - Weiss SW, Goldblum, John R. Leiomyosarcoma. 5th ed. In: Weiss S, Goldblum W, John R. editors. Soft tissue tumors. Philadelphia: Mosby Elsevier; 2008.p. 1258. ID - ref7 ER - TY - JOUR AU - Gladdy, R. A. PY - 2013 DA - 2013// TI - Predictors of survival and recurrence in primary leiomyosarcoma JO - Ann Surg Oncol VL - 20 UR - https://doi.org/10.1245/s10434-013-2876-y DO - 10.1245/s10434-013-2876-y ID - Gladdy2013 ER - TY - JOUR AU - Lambert, L. A. PY - 2008 DA - 2008// TI - Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-08-1333 DO - 10.1158/0008-5472.CAN-08-1333 ID - Lambert2008 ER - TY - STD TI - Gupta, A, Yao S, Mackay H, Hopkins L. Chemotherapy (i.e., gemcitabine, docetaxel plus gemcitabine, doxorubicin, or trabectedin) for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma, in a quaility initiative of the program in Evidence-Based Care (PEBC). Cancer Care Ontario; 2012. ID - ref10 ER - TY - JOUR AU - Hensley, M. L. PY - 2011 DA - 2011// TI - Role of chemotherapy and biomolecular therapy in the treatment of uterine sarcomas JO - Best Pract Res Clin Obstet Gynaecol VL - 25 UR - https://doi.org/10.1016/j.bpobgyn.2011.06.003 DO - 10.1016/j.bpobgyn.2011.06.003 ID - Hensley2011 ER - TY - JOUR AU - Crose, L. E. AU - Linardic, C. M. PY - 2011 DA - 2011// TI - Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma JO - Sarcoma VL - 2011 UR - https://doi.org/10.1155/2011/756982 DO - 10.1155/2011/756982 ID - Crose2011 ER - TY - JOUR AU - Wan, X. AU - Helman, L. J. PY - 2007 DA - 2007// TI - The biology behind mTOR inhibition in sarcoma JO - Oncologist VL - 12 UR - https://doi.org/10.1634/theoncologist.12-8-1007 DO - 10.1634/theoncologist.12-8-1007 ID - Wan2007 ER - TY - JOUR AU - Pandurangan, A. K. PY - 2013 DA - 2013// TI - Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways JO - Asian Pac J Cancer Prev APJCP VL - 14 UR - https://doi.org/10.7314/APJCP.2013.14.4.2201 DO - 10.7314/APJCP.2013.14.4.2201 ID - Pandurangan2013 ER - TY - JOUR AU - Paplomata, E. AU - O’Regan, R. PY - 2014 DA - 2014// TI - The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers JO - Ther Adv Med Oncol VL - 6 UR - https://doi.org/10.1177/1758834014530023 DO - 10.1177/1758834014530023 ID - Paplomata2014 ER - TY - JOUR AU - Sarris, E. G. AU - Saif, M. W. AU - Syrigos, K. N. PY - 2012 DA - 2012// TI - The biological role of PI3K pathway in lung cancer JO - Pharmaceuticals VL - 5 UR - https://doi.org/10.3390/ph5111236 DO - 10.3390/ph5111236 ID - Sarris2012 ER - TY - JOUR AU - Liu, P. PY - 2009 DA - 2009// TI - Targeting the phosphoinositide 3-kinase pathway in cancer JO - Nat Rev Drug Discov VL - 8 UR - https://doi.org/10.1038/nrd2926 DO - 10.1038/nrd2926 ID - Liu2009 ER - TY - JOUR AU - Bowles, D. W. AU - Jimeno, A. PY - 2011 DA - 2011// TI - New phosphatidylinositol 3-kinase inhibitors for cancer JO - Expert Opin Investig Drugs VL - 20 UR - https://doi.org/10.1517/13543784.2011.562192 DO - 10.1517/13543784.2011.562192 ID - Bowles2011 ER - TY - JOUR AU - Ando, Y. PY - 2014 DA - 2014// TI - Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors JO - Cancer Sci VL - 105 UR - https://doi.org/10.1111/cas.12350 DO - 10.1111/cas.12350 ID - Ando2014 ER - TY - JOUR AU - Molife, L. R. PY - 2014 DA - 2014// TI - Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors JO - J Hematol Oncol VL - 7 UR - https://doi.org/10.1186/1756-8722-7-1 DO - 10.1186/1756-8722-7-1 ID - Molife2014 ER - TY - JOUR AU - Guenther, M. K. AU - Graab, U. AU - Fulda, S. PY - 2013 DA - 2013// TI - Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma JO - Cancer Lett VL - 337 UR - https://doi.org/10.1016/j.canlet.2013.05.010 DO - 10.1016/j.canlet.2013.05.010 ID - Guenther2013 ER - TY - JOUR AU - Renshaw, J. PY - 2013 DA - 2013// TI - Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo JO - Clin Cancer Res Off J Am Assoc Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-0850 DO - 10.1158/1078-0432.CCR-13-0850 ID - Renshaw2013 ER - TY - JOUR AU - Leroy, C. AU - Amante, R. J. AU - Bentires-Alj, M. PY - 2014 DA - 2014// TI - Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine JO - Biochem Soc Trans VL - 42 UR - https://doi.org/10.1042/BST20140034 DO - 10.1042/BST20140034 ID - Leroy2014 ER - TY - JOUR AU - Janik, P. AU - Briand, P. AU - Hartmann, N. R. PY - 1975 DA - 1975// TI - The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors JO - Cancer Res VL - 35 ID - Janik1975 ER - TY - JOUR AU - Maira, S. M. PY - 2008 DA - 2008// TI - Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity JO - Mol Cancer Ther VL - 7 UR - https://doi.org/10.1158/1535-7163.MCT-08-0017 DO - 10.1158/1535-7163.MCT-08-0017 ID - Maira2008 ER - TY - JOUR AU - Chou, T. C. PY - 2006 DA - 2006// TI - Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies JO - Pharmacol Rev VL - 58 UR - https://doi.org/10.1124/pr.58.3.10 DO - 10.1124/pr.58.3.10 ID - Chou2006 ER - TY - JOUR AU - Chou, T. C. PY - 2010 DA - 2010// TI - Drug combination studies and their synergy quantification using the Chou–Talalay method JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-09-1947 DO - 10.1158/0008-5472.CAN-09-1947 ID - Chou2010 ER - TY - JOUR AU - Brachmann, S. M. PY - 2012 DA - 2012// TI - Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations JO - Mol Cancer Ther VL - 11 UR - https://doi.org/10.1158/1535-7163.MCT-11-1021 DO - 10.1158/1535-7163.MCT-11-1021 ID - Brachmann2012 ER - TY - JOUR AU - Maira, S. M. PY - 2012 DA - 2012// TI - Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor JO - Mol Cancer Ther VL - 11 UR - https://doi.org/10.1158/1535-7163.MCT-11-0474 DO - 10.1158/1535-7163.MCT-11-0474 ID - Maira2012 ER - TY - JOUR AU - Gibault, L. PY - 2012 DA - 2012// TI - From PTEN loss of expression to RICTOR role in smooth muscle differentiation: complex involvement of the mTOR pathway in leiomyosarcomas and pleomorphic sarcomas JO - Mod pathol Off J United States Can Acad Pathol Inc VL - 25 ID - Gibault2012 ER - TY - JOUR AU - Ryan, C. W. AU - Desai, J. PY - 2013 DA - 2013// TI - The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma JO - Am Soc Clin Oncol Educ Book VL - 2013 UR - https://doi.org/10.1200/EdBook_AM.2013.33.e386 DO - 10.1200/EdBook_AM.2013.33.e386 ID - Ryan2013 ER - TY - JOUR AU - Gutierrez, A. PY - 2011 DA - 2011// TI - Aberrant AKT activation drives well-differentiated liposarcoma JO - Proc Natl Acad Sci USA VL - 108 UR - https://doi.org/10.1073/pnas.1106127108 DO - 10.1073/pnas.1106127108 ID - Gutierrez2011 ER - TY - JOUR AU - Ellis, L. PY - 2013 DA - 2013// TI - Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer JO - Oncotarget VL - 4 UR - https://doi.org/10.18632/oncotarget.1314 DO - 10.18632/oncotarget.1314 ID - Ellis2013 ER - TY - JOUR AU - Reddy, L. H. AU - Murthy, R. S. PY - 2004 DA - 2004// TI - Pharmacokinetics and biodistribution studies of Doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles synthesized by two different techniques JO - Biomed Pap Med Fac Univ Palacky Olomouc Czechoslovakia VL - 148 UR - https://doi.org/10.5507/bp.2004.029 DO - 10.5507/bp.2004.029 ID - Reddy2004 ER - TY - JOUR AU - Synold, T. W. AU - Doroshow, J. H. PY - 1996 DA - 1996// TI - Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-h continuous intravenous infusion JO - J Infus Chemother VL - 6 ID - Synold1996 ER - TY - JOUR AU - Gibault, L. PY - 2011 DA - 2011// TI - New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics JO - J Pathol VL - 223 UR - https://doi.org/10.1002/path.2787 DO - 10.1002/path.2787 ID - Gibault2011 ER - TY - JOUR AU - Bendell, J. C. PY - 2012 DA - 2012// TI - Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors JO - J Clin Oncol Off J Am Soc Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.36.1360 DO - 10.1200/JCO.2011.36.1360 ID - Bendell2012 ER - TY - JOUR AU - Janku, F. PY - 2012 DA - 2012// TI - PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations JO - J Clin Oncol Off J Am Soc Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.36.1196 DO - 10.1200/JCO.2011.36.1196 ID - Janku2012 ER - TY - JOUR AU - Serra, V. PY - 2008 DA - 2008// TI - NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-08-1385 DO - 10.1158/0008-5472.CAN-08-1385 ID - Serra2008 ER - TY - JOUR AU - Santiskulvong, C. PY - 2011 DA - 2011// TI - Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma JO - Clin Cancer Res Off J Am Assoc Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-10-2289 DO - 10.1158/1078-0432.CCR-10-2289 ID - Santiskulvong2011 ER - TY - JOUR AU - Cao, P. PY - 2009 DA - 2009// TI - Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts JO - Br J Cancer VL - 100 UR - https://doi.org/10.1038/sj.bjc.6604995 DO - 10.1038/sj.bjc.6604995 ID - Cao2009 ER - TY - JOUR AU - Preuss, E. PY - 2013 DA - 2013// TI - Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein JO - J Biol Chem VL - 288 UR - https://doi.org/10.1074/jbc.M113.495986 DO - 10.1074/jbc.M113.495986 ID - Preuss2013 ER - TY - JOUR AU - Manara, M. C. PY - 2010 DA - 2010// TI - NVP-BEZ235 as a new therapeutic option for sarcomas JO - Clin Cancer Res Off J Am Assoc Cancer Res VL - 16 UR - https://doi.org/10.1158/1078-0432.CCR-09-0816 DO - 10.1158/1078-0432.CCR-09-0816 ID - Manara2010 ER - TY - JOUR AU - Kirstein, M. M. PY - 2013 DA - 2013// TI - Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma JO - Liver Int Off J Int Assoc Study Liver VL - 33 UR - https://doi.org/10.1111/liv.12126 DO - 10.1111/liv.12126 ID - Kirstein2013 ER - TY - JOUR AU - Kim, S. PY - 2012 DA - 2012// TI - Efficacy of phosphatidylinositol-3 kinase inhibitors in a primary mouse model of undifferentiated pleomorphic sarcoma JO - Sarcoma VL - 2012 UR - https://doi.org/10.1155/2012/680708 DO - 10.1155/2012/680708 ID - Kim2012 ER - TY - JOUR AU - Sheng, S. AU - Qiao, M. AU - Pardee, A. B. PY - 2009 DA - 2009// TI - Metastasis and AKT activation JO - J Cell Physiol VL - 218 UR - https://doi.org/10.1002/jcp.21616 DO - 10.1002/jcp.21616 ID - Sheng2009 ER - TY - JOUR AU - West, K. A. AU - Castillo, S. S. AU - Dennis, P. A. PY - 2002 DA - 2002// TI - Activation of the PI3K/Akt pathway and chemotherapeutic resistance JO - Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother VL - 5 UR - https://doi.org/10.1016/S1368-7646(02)00120-6 DO - 10.1016/S1368-7646(02)00120-6 ID - West2002 ER -